Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gaush MeditechHKSE:02407 +0.61%67 EBITDA Margin % is 14.25% as of Dec. 2025, which is 13% below its 10-year median of 16.31. GuruFocus rates HKSE:02407 with a GF Score™ of 67/100 and a GF Value™ of HK$13.39 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Gaush Meditech ranks better than 68.59% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gaush Meditech's EBITDA for the
six
months ended in Dec. 2025 was HK$114 Mil. Gaush Meditech's Revenue for the
six
months ended in Dec. 2025 was HK$803 Mil. Therefore, Gaush Meditech's EBITDA margin for the quarter that ended in Dec. 2025 was 14.25%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gaush Meditech EBITDA Margin % Related Terms
Gaush Meditech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gaush Meditech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02407 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Gaush Meditech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gaush Meditech (HKSE:02407) has a EBITDA Margin % of 14.25% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gaush Meditech and its competitors. This is 13% below median its historical median of 16.31. According to the industry distribution chart, Gaush Meditech ranks #256 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 31.4%.
Is Gaush Meditech's EBITDA Margin % too high?
Gaush Meditech's current EBITDA Margin % of 14.25% is 13% below median its 10-year median of 16.31. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Gaush Meditech's value of 14.25% is 90.8% above this industry median. Based on the distribution chart, Gaush Meditech ranks #256 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gaush Meditech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #256 out of 815 companies for EBITDA Margin %. This puts Gaush Meditech in the upper half of its industry. The industry median EBITDA Margin % is 7.47. Gaush Meditech's value of 14.25% is 90.8% above this benchmark. While the company's 10-year median is 16.31 vs. the industry median of 7.47, Gaush Meditech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gaush Meditech's current EBITDA Margin % of 14.25% is 90.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gaush Meditech and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current EBITDA Margin % is 14.25%, which is 13% below median its own 10-year median of 16.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Based on GuruFocus' analysis, Gaush Meditech (HKSE:02407) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.39, compared to a current price of HK$4.96 — trading 63% below its estimated fair value. The current EBITDA Margin % is 14.25%, which is 13% below median its 10-year median of 16.31 and 90.8% above the Medical Devices & Instruments industry median of 7.47. Gaush Meditech's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gaush Meditech (HKSE:02407), the current EBITDA Margin % is 14.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (HKSE:02407) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of HK$4.96 is trading 63% below its estimated GF Value™ of HK$13.39.
GuruFocus considers Gaush Meditech to be Possible Value Trap.
Key valuation signals for HKSE:02407:
EBITDA Margin %: 14.25% (13% below median its 10-year median of 16.31)
GF Value™: HK$13.39 vs. price of HK$4.96 (63% below fair value)
Industry Position: 90.8% above the Medical Devices & Instruments median (#256 of 815)
No single metric tells the full story. See the HKSE:02407 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
67GF Score
Get the complete analysis for HKSE:02407
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02407 has been successfully added to your 
